Justices Urged To Clarify Patent Validity In Entresto Case

By Editorial Team

Generic-drug makers, academics, and other stakeholders are calling on the U.S. Supreme Court to review a case involving Novartis' popular cardiovascular drug Entresto. They argue that the Court needs to address conflicting Federal Circuit rulings regarding the role of later technology in determining patent validity.

The case has garnered attention from various parties, including Sigmapharm, PIPLI, Biophore, Unified Patents, and the Association for Accessible Medicines. These entities have submitted briefs urging the Supreme Court to provide clarity on the issue.

At the heart of the matter is patent number 8,101,659, which covers methods of treatment and pharmaceutical composition related to Entresto. The case has attracted legal representation from firms such as Crowell & Moring, Jenner & Block, Morrison & Foerster, Polsinelli PC, Upadhye Tang, and Yetter Coleman.

The Supreme Court's decision to take up this case could have far-reaching implications for the pharmaceutical industry and intellectual property law. Stakeholders are eagerly awaiting the Court's response to the calls for clarification on patent validity standards.